What is BPC-157/TB-500 Blend?
BPC-157/TB-500 Blend is a research-grade combination product containing 10 mg of BPC-157 (Body Protection Compound-157) and 10 mg of TB-500 (a synthetic fragment of Thymosin Beta-4) co-lyophilized in a single vial. This blend pairs two of the most extensively studied regenerative peptides in preclinical research, each with complementary mechanisms of action targeting tissue repair and recovery.
BPC-157, also known by its research designations PL 14736 and PLD-116, is a synthetic pentadecapeptide consisting of 15 amino acids with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val and a molecular weight of approximately 1,419 Da. It is derived from a partial sequence of the human gastric juice protein known as Body Protection Compound. BPC-157 is notable for its remarkable stability in human gastric juice, distinguishing it from many other bioactive peptides that degrade rapidly in acidic conditions (Sikiric et al., 2018).
TB-500 is a synthetic version of the active region of Thymosin Beta-4 (Tβ4), a 43-amino acid peptide with a molecular weight of approximately 4,963 Da. Thymosin Beta-4 is the most abundant member of the beta-thymosin family and is the principal actin-sequestering protein in mammalian cells. It is expressed in virtually all cell types and plays a central role in cell migration, angiogenesis, and wound healing (Goldstein et al., 2012). By combining these two peptides in one vial, researchers can investigate their potentially synergistic effects on tissue repair without the need for separate reconstitution and administration protocols.
Mechanism of Action
The BPC-157/TB-500 Blend brings together two distinct yet complementary molecular pathways that converge on tissue repair and regeneration. Understanding each peptide’s mechanism provides insight into why researchers find this combination particularly compelling.
BPC-157 Mechanism
BPC-157 exerts its regenerative effects through multiple overlapping signaling cascades. Research has demonstrated that BPC-157 upregulates VEGFR2 (vascular endothelial growth factor receptor 2) expression and promotes its internalization, activating the VEGFR2-Akt-eNOS signaling pathway. This cascade drives angiogenesis — the formation of new blood vessels — which is essential for delivering oxygen and nutrients to injured tissue (Hsieh et al., 2017). Studies have also shown that BPC-157 activates the FAK-paxillin pathway, which promotes tendon fibroblast migration and cell spreading — critical steps in connective tissue repair (Chang et al., 2011). Additionally, BPC-157 dose- and time-dependently increases growth hormone receptor expression in tendon fibroblasts at both the mRNA and protein levels, potentially amplifying growth-factor-mediated healing signals (Chang et al., 2014).
BPC-157 also interacts extensively with the nitric oxide (NO) system, modulating vasomotor tone and maintaining vascular integrity. This NO-system interaction is considered central to BPC-157’s cytoprotective and organoprotective properties across multiple organ systems (Seiwerth et al., 2014).
TB-500 (Thymosin Beta-4) Mechanism
TB-500 operates through a fundamentally different primary mechanism. As the major intracellular G-actin-sequestering peptide, Thymosin Beta-4 regulates actin polymerization, which is essential for cytoskeletal dynamics, cell motility, and tissue remodeling. After injury, Tβ4 is released by platelets, macrophages, and other cell types to protect damaged tissue from further degradation and to initiate the repair cascade (Goldstein et al., 2012).
Tβ4 promotes the mobilization, migration, and differentiation of stem and progenitor cells to the injury site. It stimulates keratinocyte migration, promotes new blood vessel formation, and increases collagen deposition at wound sites. Importantly, Tβ4 also reduces scar formation by decreasing the number of myofibroblasts in healing wounds (Malinda et al., 1999). Its anti-inflammatory properties are mediated in part through inhibition of NF-κB activation and downstream inflammatory cytokine production.
Synergistic Rationale
The combination is of particular research interest because BPC-157 tends to act locally at the injury site, concentrating its effects on the immediate area of tissue damage, while TB-500 exerts more systemic effects, promoting cell migration from distant sites and modulating inflammation throughout the body. Together, they address tissue repair at both the local and systemic levels, potentially providing more comprehensive regenerative coverage than either peptide alone. Both peptides independently promote angiogenesis through distinct pathways — BPC-157 via VEGFR2-Akt-eNOS and TB-500 via actin-dependent endothelial cell migration — suggesting the possibility of additive or synergistic vascular repair.
Research Applications
The BPC-157/TB-500 Blend has attracted significant research interest across multiple areas of tissue repair and regeneration. Below are the primary research domains where this combination is being investigated. For a comprehensive overview of peptide stacking strategies, see our guide on best peptide stack combinations.
Tendon and Ligament Repair
Tendon and ligament injuries present a significant challenge due to the hypovascular and hypocellular nature of these connective tissues. BPC-157 has been shown to accelerate Achilles tendon healing in rats, improving biomechanical outcomes including load to failure and Young’s modulus of elasticity, while promoting superior fibroblast formation, reticulin deposition, and collagen organization (Staresinic et al., 2003). BPC-157 also improved medial collateral ligament healing across a 90-day observation period following surgical transection (Cerovecki et al., 2010). TB-500 contributes to this research area by promoting the migration of repair cells to the injury site through its actin-regulatory functions. The combination is studied for its potential to provide both local tissue scaffolding support (BPC-157) and systemic cell recruitment (TB-500). Researchers interested in joint and connective tissue applications can also explore our article on peptides for joint pain research.
Wound Healing and Dermal Repair
Both peptides have individually demonstrated robust wound healing properties. Tβ4 increased re-epithelialization by up to 61% over controls in rat full-thickness wound models and stimulated keratinocyte migration 2–3 fold at concentrations as low as 10 pg (Malinda et al., 1999). Tβ4 accelerated dermal healing across multiple animal models, including normal rats and mice, steroid-treated rats, diabetic mice, and aged mice (Treadwell et al., 2012). BPC-157 has similarly been effective in wound healing across a wide range of injury models, with effects that mirror its broader cytoprotective actions (Seiwerth et al., 2021). The combination is of interest for research into complex wounds where both vascular supply and cellular migration are compromised. For more on this research area, see peptides for wound healing research.
Muscle Recovery and Injury
Skeletal muscle injuries represent another key area of investigation for this blend. BPC-157 has shown efficacy in muscle crush injury models, improving functional recovery and histological outcomes. A comprehensive review of BPC-157’s musculoskeletal applications noted consistent positive effects across various injury types, including both traumatic and systemic muscle damage (Gwyer et al., 2019). TB-500’s ability to regulate actin dynamics is particularly relevant to muscle repair, as actin is a fundamental structural protein in muscle fibers. The blend is studied for post-injury muscle recovery protocols in animal models.
Gastrointestinal Protection and Gut Healing
BPC-157 was originally characterized as a cytoprotective anti-ulcer peptide, and it maintains gastric mucosal integrity against various noxious agents. It has been investigated in clinical trials for inflammatory bowel disease and has shown no toxic effects across extensive preclinical testing (Sikiric et al., 2006). While TB-500’s primary research focus is not gastrointestinal, its anti-inflammatory properties through NF-κB modulation may complement BPC-157’s gut-specific cytoprotective effects. Researchers studying gastrointestinal applications should also explore peptides for gut health research.
Anti-Inflammatory and Immunomodulatory Research
Both peptides demonstrate anti-inflammatory activity through distinct mechanisms. BPC-157 modulates inflammation through its interaction with the NO system and by reducing inflammatory cell infiltration at injury sites. TB-500 limits inflammation through multiple pathways, including autophagy induction and NF-κB inhibition. The blend is investigated in models of chronic inflammation where both local and systemic anti-inflammatory effects are desired. For broader context on inflammation-related peptide research, visit peptides for inflammation research.
Published Research Studies
While no published studies have specifically examined the BPC-157/TB-500 combination as a co-administered blend, a substantial body of research supports the individual activities of each component. Below are key published studies that inform the rationale for this combination.
1. Staresinic et al. (2003) — BPC 157 and Achilles Tendon Healing Published in the Journal of Orthopaedic Research, this study demonstrated that BPC-157 fully improved recovery of transected rat Achilles tendon across biomechanical, functional, microscopical, and macroscopical measures. Treated animals showed increased load to failure, superior collagen formation, and complete reestablishment of tendon integrity at doses ranging from 10 μg to 10 pg/kg (PMID: 14554208).
2. Chang et al. (2011) — BPC 157 Promotes Tendon Fibroblast Migration Published in the Journal of Applied Physiology, this study showed that BPC-157 accelerated tendon explant outgrowth, enhanced fibroblast survival under oxidative stress, and promoted dose-dependent cell migration. The mechanism was linked to activation of the FAK-paxillin signaling pathway (PMID: 21030672).
3. Hsieh et al. (2017) — Pro-Angiogenic Mechanism of BPC 157 Published in the Journal of Molecular Medicine, this study revealed that BPC-157 promotes angiogenesis through upregulation and internalization of VEGFR2, activating the VEGFR2-Akt-eNOS signaling cascade. BPC-157 accelerated blood flow recovery in a rat hind limb ischemia model (PMID: 27847966).
4. Malinda et al. (1999) — Thymosin Beta-4 Accelerates Wound Healing Published in the Journal of Investigative Dermatology, this landmark study demonstrated that Tβ4 enhanced wound healing by 42–61% over controls in a rat full-thickness wound model. Tβ4 increased collagen deposition, angiogenesis, and keratinocyte migration at doses as low as 10 pg (PMID: 10469335).
5. Goldstein et al. (2012) — Thymosin Beta-4: A Multi-Functional Regenerative Peptide Published in Expert Opinion on Biological Therapy, this comprehensive review detailed how Tβ4 binds actin, promotes cell migration, mobilizes stem/progenitor cells, promotes angiogenesis, and decreases scar formation through reduced myofibroblast activity. Clinical applications in skin, eye, heart, and brain were discussed (PMID: 22074294).
Dosage Protocols in Research
The following dosage information is derived exclusively from published animal and in vitro studies and is provided for research reference purposes only. This information does not constitute medical advice or dosing recommendations for human use.
BPC-157 Research Dosages
In preclinical studies, BPC-157 has been administered at a wide range of doses via intraperitoneal (i.p.) injection. Commonly reported dosages in rat models include 10 μg/kg, 10 ng/kg, and even 10 pg/kg body weight, administered once daily. Staresinic et al. (2003) used daily i.p. injections at these three dose levels and observed significant tendon healing improvements at all concentrations. BPC-157 has also been studied via oral administration (in drinking water) and topical application, maintaining efficacy across delivery routes due to its exceptional stability in gastric juice.
TB-500 Research Dosages
In published wound healing studies, Tβ4 has been administered both topically and intraperitoneally. Malinda et al. (1999) applied Tβ4 topically at concentrations of 5 μg per wound or intraperitoneally at 60 μg per rat in wound healing models. In vitro migration assays demonstrated activity at concentrations as low as 10 pg.
Reconstitution
The BPC-157/TB-500 Blend (10 mg/10 mg) should be reconstituted with bacteriostatic water. Slowly inject the bacteriostatic water along the inside wall of the vial, allowing the lyophilized powder to dissolve without excessive agitation. Gently swirl the vial — do not shake vigorously — until the solution is clear. For detailed reconstitution instructions, refer to our guide on how to reconstitute peptides.
Storage and Handling
Proper storage is essential to maintain the stability and integrity of the BPC-157/TB-500 Blend. Follow these guidelines to preserve peptide quality:
Lyophilized (unreconstituted) powder: Store at -20°C for long-term storage (up to 24 months) or at 2–8°C (refrigerated) for short-term storage (up to 6 months). Keep the vial sealed and away from light and moisture. Reconstituted solution: Store at 2–8°C (refrigerated) and use within 4–6 weeks for optimal stability. Do not freeze reconstituted peptide solutions, as freeze-thaw cycles can cause protein aggregation and degradation. General handling: Always use sterile techniques when handling peptide solutions. Use alcohol swabs to clean vial stoppers before each withdrawal. Avoid repeated insertion of needles, which can introduce particulate contamination. Light sensitivity: Both peptides may degrade with prolonged light exposure. Store vials in their original packaging or wrap in aluminum foil when not in use.
BPC-157 is notably stable in acidic conditions, a property that distinguishes it from most bioactive peptides. However, standard cold-chain storage practices should still be observed for the reconstituted blend. For comprehensive storage guidance, see our article on how to store research peptides.
Safety Profile in Research
Both BPC-157 and TB-500 have demonstrated favorable safety profiles across extensive preclinical testing, which is a primary reason this combination has attracted widespread research interest.
BPC-157 Safety Data: BPC-157 has been described as having no toxic effects in published literature. Sikiric et al. (2006) noted that BPC-157 was used in clinical trials for ulcerative colitis (as PLD-116) with no reported side effects (Sikiric et al., 2006). In comprehensive preclinical studies across multiple organ systems, BPC-157 demonstrated an absence of adverse effects even at very high doses. Gwyer et al. (2019) noted in their systematic review that “there are few studies reporting any adverse reactions to the administration of BPC 157” (Gwyer et al., 2019). Lethal dose (LD1) could not be achieved in standard toxicology testing protocols.
TB-500 Safety Data: Thymosin Beta-4 is a naturally occurring peptide found in high concentrations in blood platelets, wound fluid, and most mammalian cell types. As an endogenous molecule, it has an inherently favorable safety profile. Clinical trials of Tβ4 for dermal wound healing and corneal repair have reported minimal adverse effects (Treadwell et al., 2012). However, because Tβ4 promotes angiogenesis and cell migration, researchers should be cautious in models involving existing neoplastic conditions, as these processes could theoretically promote tumor growth.
Blend Considerations: When using the combined product, researchers should note that while both peptides are individually well-tolerated, the interaction profile of the combination has not been independently characterized in formal toxicology studies. Standard precautions for research peptide handling should be observed. For further information on research peptide safety considerations, see our research peptide safety guide.
Related Peptides
Researchers studying the BPC-157/TB-500 Blend may also be interested in exploring the individual components and related regenerative peptides:
BPC-157 10mg — The standalone BPC-157 product for research protocols requiring only this pentadecapeptide. TB-500 10mg — The standalone Thymosin Beta-4 fragment for independent investigation. GHK-Cu 50mg — A copper-binding tripeptide involved in tissue remodeling, collagen synthesis, and wound healing through distinct mechanisms. Often studied alongside BPC-157 and TB-500 in regenerative research. Learn more in our GHK-Cu copper peptide guide. KPV 10mg — An anti-inflammatory tripeptide derived from α-MSH, studied for gut inflammation and wound healing applications. Thymosin Alpha-1 10mg — A related thymic peptide with immunomodulatory properties, distinct from Thymosin Beta-4 but sharing the thymosin family classification.
For a detailed comparison of BPC-157 and TB-500 as individual peptides, see our article on TB-500 vs BPC-157 comparison.
Frequently Asked Questions
What is BPC-157/TB-500 Blend used for in research?
The BPC-157/TB-500 Blend is used in preclinical research to investigate the combined effects of these two regenerative peptides on tissue repair. Primary research areas include tendon and ligament healing, wound repair, muscle recovery, gastrointestinal protection, and anti-inflammatory applications. The blend is designed exclusively for laboratory research and is not intended for human consumption or therapeutic use.
How do BPC-157 and TB-500 work together?
BPC-157 and TB-500 operate through complementary mechanisms. BPC-157 primarily acts locally at injury sites, promoting angiogenesis via the VEGFR2-Akt-eNOS pathway and enhancing fibroblast migration through the FAK-paxillin pathway. TB-500 works more systemically by regulating actin dynamics to promote cell migration, stem cell mobilization, and anti-inflammatory signaling. Together, they address tissue repair from both local and systemic perspectives.
What is the difference between TB-500 and Thymosin Beta-4?
TB-500 is a synthetic peptide that represents the active region of the naturally occurring 43-amino acid Thymosin Beta-4 protein. While full-length Thymosin Beta-4 has a molecular weight of approximately 4,963 Da, TB-500 replicates the key functional domain responsible for the protein’s actin-sequestering, cell migration, and wound healing activities. In research contexts, the terms are often used interchangeably, though they refer to slightly different molecular entities.
How should the BPC-157/TB-500 Blend be reconstituted?
The lyophilized blend should be reconstituted with bacteriostatic water using sterile technique. Direct the stream of water along the inner wall of the vial to avoid disrupting the peptide cake. Allow the powder to dissolve by gentle swirling rather than shaking. The reconstituted solution should be stored at 2–8°C and used within 4–6 weeks.
Is BPC-157/TB-500 Blend safe for research use?
Both peptides have demonstrated favorable safety profiles in extensive preclinical research. BPC-157 has shown no lethal dose in toxicology studies, and TB-500 is a naturally occurring endogenous peptide. However, no formal toxicology studies have been conducted on the specific combination. Researchers should follow standard laboratory safety protocols and institutional guidelines when handling research peptides.
Can BPC-157/TB-500 be combined with other peptides in research?
In preclinical research, BPC-157 and TB-500 have each been studied alongside various other compounds. Some researchers explore combinations with GHK-Cu for comprehensive tissue remodeling studies or with growth hormone secretagogues such as Ipamorelin for recovery-focused protocols. Any multi-peptide research protocol should be carefully designed with appropriate controls.
What purity level is the BPC-157/TB-500 Blend?
Iron Peak Peptides provides this blend at research-grade purity (≥99%), verified through third-party HPLC and mass spectrometry testing. Each batch is accompanied by a quality assurance documentation confirming peptide identity, purity, and sterility.
Why Buy BPC-157/TB-500 Blend from Iron Peak Peptides?
Iron Peak Peptides is committed to providing the highest quality research peptides available. Our BPC-157/TB-500 Blend (10 mg/10 mg) is manufactured to exacting standards and undergoes rigorous quality assurance at every stage of production.
Every batch is subjected to independent third-party testing using HPLC (High-Performance Liquid Chromatography) for purity verification and mass spectrometry for molecular identity confirmation. We guarantee a minimum purity of 99% for each peptide component in the blend. A detailed quality assurance documentation is available for every lot, providing complete transparency regarding peptide identity, purity, endotoxin levels, and sterility.
Our lyophilized peptide blends are produced in ISO-certified facilities and packaged in sterile, sealed vials to prevent contamination and degradation during transit and storage. We ship with appropriate cold-chain packaging to maintain product integrity from our facility to your laboratory.
Iron Peak Peptides also provides comprehensive educational resources, including detailed research guides, dosage references, and reconstitution instructions to support your research. Our customer support team is available to answer technical questions and assist with product selection. When you choose Iron Peak Peptides, you are selecting a supplier that prioritizes scientific rigor, product quality, and researcher support above all else.
References
Staresinic M, Petrovic I, Novinscak T, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. PubMed Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon fibroblast healing involves the FAK-paxillin pathway. J Appl Physiol. 2011;110(3):774-780. PubMed Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066-19077. PubMed Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC 157 is associated with VEGFR2 activation and up-regulation. J Mol Med. 2017;95(3):323-333. PubMed Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159. PubMed Seiwerth S, Milavic M, Vukojevic J, et al. Stable gastric pentadecapeptide BPC 157 and wound healing. Front Pharmacol. 2021;12:627533. PubMed Cerovecki T, Bojanic I, Brcic L, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. J Orthop Res. 2010;28(9):1155-1161. PubMed Sikiric P, Seiwerth S, Rucman R, et al. Novel cytoprotective mediator, stable gastric pentadecapeptide BPC 157. Vascular recruitment and gastrointestinal tract healing. Curr Pharm Des. 2018;24(18):1990-2001. PubMed Sikiric P, Seiwerth S, Brcic L, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease. Inflammopharmacology. 2006;14(5-6):214-221. PubMed Seiwerth S, Brcic L, Vuletic LB, et al. BPC 157 and blood vessels. Curr Pharm Des. 2014;20(7):1033-1042. PubMed Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368. PubMed Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. PubMed Philp D, Goldstein AL, Kleinman HK. Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development. Mech Ageing Dev. 2004;125(2):113-115. PubMed Treadwell T, Kleinman HK, Crockford D, Hardy MA, Guarnera GT, Goldstein AL. The regenerative peptide thymosin β4 accelerates the rate of dermal healing in preclinical animal models and in patients. Ann N Y Acad Sci. 2012;1270:37-44. PubMed
, "manufacturer": { "@type": "Organization", "name": "Iron Peak Peptides" }, "url": "http://ironpeakpeptides.com/product/bpc-157-tb-500-blend-10mg-10mg/", "category": "Research Peptides", "offers": { "@type": "Offer", "availability": "https://schema.org/InStock", "priceCurrency": "USD", "seller": { "@type": "Organization", "name": "Iron Peak Peptides", "url": "http://ironpeakpeptides.com" } } }
}, { "@type": "Question", "name": "How do BPC-157 and TB-500 work together?", "acceptedAnswer": { "@type": "Answer", "text": "BPC-157 and TB-500 operate through complementary mechanisms. BPC-157 primarily acts locally at injury sites, promoting angiogenesis via the VEGFR2-Akt-eNOS pathway and enhancing fibroblast migration through the FAK-paxillin pathway. TB-500 works more systemically by regulating actin dynamics to promote cell migration, stem cell mobilization, and anti-inflammatory signaling. Together, they address tissue repair from both local and systemic perspectives." } }, { "@type": "Question", "name": "What is the difference between TB-500 and Thymosin Beta-4?", "acceptedAnswer": { "@type": "Answer", "text": "TB-500 is a synthetic peptide that represents the active region of the naturally occurring 43-amino acid Thymosin Beta-4 protein. While full-length Thymosin Beta-4 has a molecular weight of approximately 4,963 Da, TB-500 replicates the key functional domain responsible for the proteinu2019s actin-sequestering, cell migration, and wound healing activities. In research contexts, the terms are often used interchangeably, though they refer to slightly different molecular entities." } }, { "@type": "Question", "name": "How should the BPC-157/TB-500 Blend be reconstituted?", "acceptedAnswer": { "@type": "Answer", "text": "The lyophilized blend should be reconstituted with bacteriostatic water using sterile technique. Direct the stream of water along the inner wall of the vial to avoid disrupting the peptide cake. Allow the powder to dissolve by gentle swirling rather than shaking. The reconstituted solution should be stored at 2u20138u00b0C and used within 4u20136 weeks." } }, { "@type": "Question", "name": "Is BPC-157/TB-500 Blend safe for research use?", "acceptedAnswer": { "@type": "Answer", "text": "Both peptides have demonstrated favorable safety profiles in extensive preclinical research. BPC-157 has shown no lethal dose in toxicology studies, and TB-500 is a naturally occurring endogenous peptide. However, no formal toxicology studies have been conducted on the specific combination. Researchers should follow standard laboratory safety protocols and institutional guidelines when handling research peptides." } }, { "@type": "Question", "name": "Can BPC-157/TB-500 be combined with other peptides in research?", "acceptedAnswer": { "@type": "Answer", "text": "In preclinical research, BPC-157 and TB-500 have each been studied alongside various other compounds. Some researchers explore combinations with GHK-Cu for comprehensive tissue remodeling studies or with growth hormone secretagogues such as Ipamorelin for recovery-focused protocols. Any multi-peptide research protocol should be carefully designed with appropriate controls." } }, { "@type": "Question", "name": "What purity level is the BPC-157/TB-500 Blend?", "acceptedAnswer": { "@type": "Answer", "text": "Iron Peak Peptides provides this blend at research-grade purity (u226599%), verified through third-party HPLC and mass spectrometry testing. Each batch is accompanied by a quality assurance documentation confirming peptide identity, purity, and sterility." } } ] }